» Articles » PMID: 27075444

Economic Evaluation of Mental Health Interventions: an Introduction to Cost-utility Analysis

Overview
Specialty Psychology
Date 2016 Apr 15
PMID 27075444
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Finite resources need to be allocated over an ever-increasing range of competing health policies and interventions. Economic evaluation has been developed as a methodology to inform decision makers on the efficiency of particular resource allocations. In this paper we summarize cost-utility analysis, one of the most widely-used forms of economic evaluation in healthcare. We discuss its main elements, interpretation, limitations and relevance to the domain of mental health.

Citing Articles

A systematic review of whole disease models for informing healthcare resource allocation decisions.

Jin H, Tappenden P, Ling X, Robinson S, Byford S PLoS One. 2023; 18(9):e0291366.

PMID: 37708188 PMC: 10501624. DOI: 10.1371/journal.pone.0291366.


Health Economic Evaluation of Cognitive Control Training for Depression: Key Considerations.

Neve de Mevergnies C, Verhaeghe N, Koster E, Baeken C, Vander Zwalmen Y, Hoorelbeke K JMIR Ment Health. 2023; 10:e44679.

PMID: 37594847 PMC: 10474514. DOI: 10.2196/44679.


Health care costs and changes in subjective health-related quality of life among Finnish adolescents referred to secondary psychiatric out-patient services: a one-year follow-up study.

Rissanen A, Roine R, Marttunen M, Sintonen H, Lindberg N Scand J Child Adolesc Psychiatr Psychol. 2023; 11(1):34-43.

PMID: 37273801 PMC: 10236378. DOI: 10.2478/sjcapp-2023-0004.


Assessing the validity and responsiveness of a generic preference quality of life measure in the context of posttraumatic stress disorder.

Matthews S, Elizabeth M, Roberts L, Kaambwa B, Wade T, Nixon R Qual Life Res. 2023; 32(10):2817-2827.

PMID: 37179519 PMC: 10474197. DOI: 10.1007/s11136-023-03432-y.


Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia.

Rekhi G, Saw Y, Lim K, Keefe R, Lee J Brain Sci. 2023; 13(2).

PMID: 36831758 PMC: 9954179. DOI: 10.3390/brainsci13020215.


References
1.
Taylor R, Drummond M, Salkeld G, Sullivan S . Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004; 329(7472):972-5. PMC: 524116. DOI: 10.1136/bmj.329.7472.972. View

2.
Sonnenberg F, Beck J . Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13(4):322-38. DOI: 10.1177/0272989X9301300409. View

3.
Chisholm D, Healey A, Knapp M . QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol. 1997; 32(2):68-75. DOI: 10.1007/BF00788923. View

4.
Dolan P, Gudex C, Kind P, Williams A . The time trade-off method: results from a general population study. Health Econ. 1996; 5(2):141-54. DOI: 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N. View

5.
Schokkaert E . How to introduce more (or better) ethical arguments in HTA?. Int J Technol Assess Health Care. 2015; 31(3):111-2. DOI: 10.1017/S0266462315000306. View